CPIX

$100 million Transaction Follows Cumberland Shareholder Approval Strengthens Cumberland's Focus on Rare Disease Pipeline NASHVILLE, Tenn., July 1, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a U.S. biopharmaceutical company, today announced the closing on an agreement with subsidiary of Apotex Health Corp. ("Apotex"), the largest Canadian-based pharmaceutical company, to integrate their branded U.S. businesses.

Additional cardiac biomarker analyses further demonstrate ifetroban's cardioprotective effect in DMD patients NASHVILLE, Tenn., June 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, today shared updated results from its Phase 2 FIGHT DMD trial evaluating ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the annual Parent Project Muscular Dystrophy (PPMD) conference in Orlando, Florida.

$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.

$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1  for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young children -- Rare pediatric disease designation provides for a Priority Review Voucher (PRV) subject to certain conditions -- This new designation is in addition to opaganib's current neuroblastoma orphan drug designation, providing for potential benefits such as accelerated development and review times, FDA Prescription Drug User Fee Act (PDUFA) application fee waivers, tax credits and seven-years' marketing exclusivity, if approved -- New preclinical data, presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, showed positive effects of opaganib as a potential add-on therapy in models of neuroblastoma and triple-negative breast cancer (TNBC) 2 -- The neuroblastoma market is expected to be valued at approximately $3.5 billion in 2032 3 -- Opaganib is a novel, potentially broad acting, oral, small molecule drug with demonstrated safety & efficacy profiles 4 . It is in development for multiple oncology, viral (including Ebola virus disease (EVD)), inflammatory and diabetes and obesity-related indications RALEIGH, N.C.

CPIX reports positive Phase 2a results for Ifetroban, showing a favorable safety profile and promising early signs of reducing cancer metastasis in high-risk patients.

CPIX launches Vibativ in China through SciClone, expanding access to its antibiotic treatment for serious Gram-positive bacterial infections.

Positive Results from Phase 2a Clinical Trial Study met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumors Trial revealed promising efficacy signals with fewer deaths due to metastasis in the ifetroban arm, than in the placebo arm (p=0.037) Results support development of ifetroban as a candidate for metastasis prevention NASHVILLE, Tenn., June 2, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, and Vanderbilt Health today announce data from a Phase 2a clinical trial of ifetroban to prevent metastasis in high-risk solid tumors.

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib 1 , including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform Opaganib EVD rationale (analogous to EVD treatment pathway): Phase 3 clinical antiviral activity (severe COVID-19) showing 2 : 70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo + SoC (p=0.034)) Improved median time to viral RNA clearance by ≥4 days in opaganib-treated patients (median 10 days vs.

Commercialization in China through partnership with SciClone Pharmaceuticals Expands access to potentially life-saving antibiotic  in the world's second-largest pharmaceutical market NASHVILLE, Tenn., May 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation focused biopharmaceutical company, today announced the launch of its Vibativ® (telavancin) injection in China, following regulatory approval and a strategic partnership with SciClone Pharmaceuticals (Holdings) Limited.